Clinical Trials Browser

Phase 1 × Interventional × Tablets × Clear all

NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Phase 1 Recruiting

Other solid neoplasm

TP53 Y220C Mutation

NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Phase 1 Terminated

47 enrolled 43 charts

Neoplasms, Neuroblastoma, Osteosarcoma

NCT03544905 2025-04-22

Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Phase 1 Withdrawn

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1 Completed

168 enrolled 59 charts

GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01149720 2019-02-12

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT01173913 2019-01-10

Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir

Phase 1 Completed

Neoplasms

NCT03156127 2017-08-10

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Phase 1 Withdrawn

Myofibroma

NCT02536391 2016-11-02

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Phase 1 Completed

Neoplasms

NCT00941863 2016-03-22

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Phase 1 Completed

158 enrolled 17 charts

Carcinoma

NCT02563951 2016-01-08

Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers

Phase 1 Completed

Nausea, Neoplasms, Vomiting

NCT00667485 2014-01-17

Rapamycin Plus Bevacizumab in Advanced Cancers

Phase 1 Completed

Neoplasm Metastasis

NCT01697020 2013-12-02

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Phase 1 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma